CODEN [USA]: IAJPBB ISSN: 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

http://doi.org/10.5281/zenodo.3476822

Available online at: http://www.iajps.com *Research Article*

PULMONARY FUNCTION TEST AND ITS CORRELATION WITH HBA1C LEVELS IN CASES OF TYPE-II DIABETES MELLITUS.

[1]**Dr. Anjum Naveed,** [2]**Dr. Sh. Khurram Salam Sehgal,** [3]**Dr. Naseem Jahan Qaisrani**

[1]Associate Professor, Department of Pulmonology, Nishtar Medical University, Multan., [2]Associate Professor, Department of Biochemistry, Sheikh Zayed Medical College, Rahim Yar Khan., [3]Department of Physiology, DG Khan Medical College, DG Khan.

Article Received: August 2019 **Accepted:** September 2019 **Published:** October 2019

Abstract:

Objective: *To assess the pulmonary function test in cases of type-II diabetics and its association with HbA1c levels.*

Material and methods: *This cross sectional study was conducted at Department of Pulmonology, Nishtar Hospital, Multan from January 2018 to June 2018. Total 67 type-II diabetics were having age 30-60 years either male or female were selected for this study.*

Results: *Mean age of the type-II diabetics was 50.3±7.14 years. Mean FBS was 114.8±17.5mg/dl while mean PPBS was 151.6±23.8mg/dl. Total 10 (15%) patients belonged to age group 30-40 years followed by 23 (34%) patients belonged to age group 41-50 years and 34 (51%) patients belonged to age group 51-60 years. Out of 67 diabetics, male patients were 36 (54%) and female patients were 31 (46%).*

Conclusion: *Results of present study showed most of the patients belonged to 6th decade of life, male patients found with higher number as compared to female patients. In most of the diabetics, pulmonary function test was normal. Higher number of patients found with abnormal HbA1c levels.*

Corresponding author:

Anjum Naveed,

Associate Professor, Department of Pulmonology,
Nishtar Medical University, Multan.

QR code

Please cite this article in press Anjum Naveed et al., ***Pulmonary Function Test and Its Correlation with Hba1c Levels in Cases of Type-II Diabetes Mellitus.,*** *Indo Am. J. P. Sci, 2019; 06(10).*

INTRODUCTION:

Diabetes mellitus (DM) is a group of metabolic disorders characterized by hyperglycemia and deranged metabolism of carbohydrates, lipids and protein that result from insensitivity to endogenous insulin. [1] It is increasing in epidemic proportions throughout the world and positioned a significant economic burden over them. It is a substantial global health problem and markedly increases morbidity and mortality of the affected people. [2] As per the International Diabetes Federation prediction, in 2014 at least 387million people were living with diabetes mellitus and by the year 2035, this number will climb to almost 600million people, thus affecting more than one in 10 adults worldwide. [3] As a metabolic disorder, diabetes is accompanied by widespread biochemical, morphological and functional abnormalities and affects nearly all systems in the human body. The complications resulting from the disease are a significant cause of morbidity and mortality and are associated with the damage or failure of various organs such as the eyes, kidneys and nerves. Individuals with type 2 diabetes are also at a significantly higher risk for coronary heart disease, peripheral vascular disease, stroke and they have a greater likelihood of having hypertension, dyslipidemia, and obesity.1 Type 2 diabetes mellitus is associated with the development of microvascular and macrovascular complications. [4]

The development of these complications can be explained by the biochemical adjustment in connective tissue as well as by microangiopathy due to protein glycosylation induced by chronic hyperglycemia. [5] Macrovascular complications lead to a spectrum of cardiovascular disease to which accelerated atherosclerosis is usually a contributor. The risk of cardiovascular diseases is doubled in diabetes mellitus. [6] The macrovascular complications of diabetes mellitus include coronary artery disease (leading to ischemic heart disease-angina and myocardial infarction), peripheral vascular disease (leading to intermittent claudication and diabetic foot), diabetic myonecrosis and strokes. [7] The microvascular changes result in diabetic retinopathy, diabetic nephropathy, diabetic neuropathy and diabetic cardiomyopathy. [8] Chronic hyperglycemia in diabetes may lead to systemic inflammation which results in airway and lung damage. [9] As a proinflammatory stimulus, chronic hyperglycemia leads to increased intrapulmonary inflammation and tissue fibrosis. Structural modifications of the lung parenchyma that result from these changes include the narrowing of the alveolar space, flattening of the alveolar epithelium and expansion of the interstitial.

The result is a reduction of lung volumes and pulmonary diffusion capacity. [10] T2DM individuals are known to have reduced exercise capacity and the level of reduction is associated with diabetes control. The pulmonary and other late complications of diabetes share a similar microangiopathy mechanism. Since, they share common mechanisms, there may be associations between lung function and markers of microangiopathy. [11]

The association between pulmonary function in T2DM and duration of diabetes, adequacy of glycemic control and body composition is inconclusive. Some studies have concluded that impaired lung function is negatively associated with impaired glycemic status and duration of diabetes. [12] Few studies showed that DM is associated with statistically significant, impaired pulmonary function in a restrictive pattern but these results were irrespective of body mass index (BMI), smoking, duration of diabetes and HbA1c levels. [13]

Although a lot of research work is being carried out on the prevalence of chronic complications of T2DM worldwide, there is a dearth of information in literature pertaining to the prevalence of impaired lung function in people with T2DM. Globally, the association between indices of microvascular disease and lung function in T2DM are also not extensively studied. Present study is a relevant step towards the future to overcome the lacuna in this field with the aim to measure pulmonary function tests in patients of diabetes mellitus and to correlate HbA1c levels of these patients with various parameters of pulmonary function tests. The results of this study will help bridge the knowledge gap and provide population relevant data on the pulmonary function and related factors in T2DM.

MATERIAL AND METHODS:

This cross sectional study was conducted at Department of Pulmonology, Nishtar Hospital, Multan from January 2018 to June 2018. Total 67 type-II diabetics were having age 30-60 years either male or female were selected for this study. Patients with complaints of a cough, sputum, or dyspnea, history of smoking, any ischemic and valvular heart disease, with chronic occupational exposure and deformities as kyphoscoliosis were excluded from this study. Approval was taken from ethical committee and written informed consent was taken from every patient.

Subject's brief history of the condition was sought and detailed clinical examination was performed. Patients FBS, PPBS were analyzed by glucose oxidase (GOD), peroxidase (POD) methods in ILAB 650 analyzer and HbA1C was analyzed using HPLC. Pulmonary function test was conducted in all the subjects using the spirometer which was the gold standard for accurate and repeatable measurement of lung function.

Data were expressed as a percentage and mean±SD. Student's t-test was used to check the significance of the difference between two parameters in parametric data. Pearson correlation analysis was performed to check the correlation between two categorical variables. Fischer's exact test or Chi-square test was used to analyze the significance of the difference between frequency distribution of the data. A p-value <0.05 was considered as statistically significant.

RESULTS:

Mean age of the type-II diabetics was 50.3±7.14 years. Mean FBS was 114.8±17.5mg/dl while mean PPBS was 151.6±23.8mg/dl. Patients were divided into 3 age groups i.e. age group 30-40 years, age group 41-50 years and age group 51-60 years. Total 10 (15%) patients belonged to age group 30-40 years followed by 23 (34%) patients belonged to age group 41-50 years and 34 (51%) patients belonged to age group 51-60 years. (Fig. 1) Out of 67 diabetics, male patients were 36 (54%) and female patients were 31 (46%). (Fig. 2)

Most of the subject having abnormal high HbA1c (n=48, 71.6%). A large population of subjects having duration of DM ≤10years (n=47, 70.1%) while n=20 (29.9%) subject having diabetes for >20years. Majority of the subjects having normal BMI (n=47, 70.1%) and normal pulmonary function (n=57, 85.1%). The restrictive pulmonary function was found in 10 (14.9%) subjects (Table 1).

The age was significantly higher (P=0.013) in subjects with a restrictive pattern of PFT and the duration of diabetes was significantly longer in restrictive pulmonary function pattern (P<0.0001). There was no significant difference found between two groups regarding rest of the parameters (BMI, HbA1c, FBS and PPBS) (Table 2).

FVC (L) P having mild downstream (r= -0.247, P=0.044*) with age and duration of disease (r= -0.247, P=0.044*). FVC (L)%P and FVC (L)% showing mild correlation (r=-0.400, P=0.001** and r=-0.393, P=0.001** respectively) with duration of disease. FEV1 (L) P and FEV1/FVC%P showing mild downstream (r= -0.260, P=0.033* and r=-0.320, P=0.008*respectively) with duration of disease (Table 3).

Fig. 1: Age distribution of patients.



Fig. 2: Gender distribution



Table 1: Clinical variables in study subjects.

Variables		N	%
HbA1c	≤ 6.5	19	28.4
	>6.5	48	71.6
Duration of diabetes (yrs)	≤10	47	70.1
	>10	20	29.9
BMI (kg/m2)	Underweight	3	4.5
	Normal	47	70.1
	Overweight	15	22.4
	Obese	2	3.0
Pulmonary function	Normal	57	85.1
	Restrictive	10	14.9
	Obstructive	0	0
	Mixed	0	0

Table 2: Comparison of parameters between subjects with normal and restrictive.

Parameters	Pulmonary function	N	Mean	SD	P value
Age (yrs)	Normal	57	49.63	8.19	0.01
	Restrictive	10	54.30	4.24	
BMI	Normal	57	23.48	2.99	0.513
	Restrictive	10	24.12	1.46	
HbA1c (g%)	Normal	57	7.07	0.78	0.43
	Restrictive	10	7.28	0.77	
Duration of diabetes (yrs)	Normal	57	7.37	5.05	0.01
	Restrictive	10	13.80	4.49	
FBS (mg/dl)	Normal	57	115.23	18.22	0.52
	Restrictive	10	112.20	12.56	
PPBS (mg/dL)	Normal	57	152.18	24.81	0.68
	Restrictive	10	148.30	17.54	

Table 3: Correlation analysis of pulmonary function test with various parameters.

Pulmonary function test	Parameter	Pearson's r	P-value	Significance/interpretation
FVC (L) P	Age	-0.247	0.044*	Mild downstream
	BMI	0.141	0.25	No correlation
	HbA1C	0.032	0.79	No correlation
	Duration of Disease	-0.247	0.044*	Mild downstream
FVC (L)%P	Age	-0.208	0.09	No correlation
	BMI	0.053	0.67	No correlation
	HbA1C	-0.068	0.58	No correlation
	Duration of Disease	-0.400	<0.01**	Mild correlation
FEV1 (L) P	Age	-0.238	0.053	No correlation
	BMI	0.108	0.383	No correlation
	HbA1C	0.025	0.838	No correlation
	Duration of Disease	-0.260	0.033*	Mild downstream
FVC (L)%	Age	-0.208	0.091	No correlation
	BMI	0.056	0.651	No correlation
	HbA1C	-0.025	0.843	No correlation
	Duration of Disease	-0.393	<0.01**	Mild correlation
FEV1/FVC%P	Age	-0.192	0.119	No correlation
	BMI	-0.087	0.484	No correlation
	HbA1C	-0.046	0.709	No correlation
	Duration of Disease	-0.320	<0.01*	Mild downstream
FEV1/FVC%	Age	-0.187	0.131	No correlation
	BMI	-0.026	0.836	No correlation
	HbA1C	0.035	0.777	No correlation
	Duration of Disease	-0.087	0.483	No correlation

DISCUSSION:

Diabetes mellitus is a chronic disease associated with various micro and macrovascular complications. Present study finding showed that majority of the subjects were male, belonged to the sixth decade of life with a mean age of 50.3±7.14 years, having normal BMI and pulmonary function was normal. Pulmonary function was found to be restrictive in 14.9% subjects. Study findings show that diabetes mellitus was more common in old age group (>50years of age) and in male population (>45%) [12,14-16]

The mean FBS was 114.8±17.5mg/dl while mean PPBS was 151.6±23.8mg/dl. Majority of the subjects were having an abnormally high level of HbA1c and they had </=10years duration of DM. Few studies has

concluded that the HbA1c level in diabetic subjects remains towards the higher side (>6.5). The incidence of diabetes was increasing and most of the subjects having a diabetes duration of ≤10years. [16-18]

Pulmonary function was normal in most of the subjects and it was restrictive in 14.9% subjects. No subjects with obstructive PFT pattern were present in this study. In a prospective study by Davis W et al, mean percentage-predicted values of each spirometry measure were decreased 10% in the whole cohort at baseline and absolute measures continued to decline at an annual rate of 68, 71 and 84ml/year and 17l/min for FVC, FEV1, VC and PEF, respectively. [15] Davis W et al, reported that the means of all spirometry measures were reduced by >9.5%. [19] Yeh HC et al, reported adults with diabetes had significantly lower predicted FVC and predicted FEV1 than those without diabetes. [20] Benbassat C et al, however, reported no such significant changes in pulmonary function tests in type 2 DM subjects. [16]

Older age and longer duration of diabetes were found to be significantly associated with deranged pulmonary function tests in study subjects with diabetes mellitus. No such association of PFT was detected with BMI, HbA1c, fasting or postprandial blood sugar. Davis W et al, in their study reported similar findings stating after controlling for smoking, age and gender in a linear regression model, HbA1c was not associated with any measure of lung function but diabetes duration was significantly associated with FEV1% pred and PEF% pred and had borderline associations with FVC% pred and VC% pred. [19] Shah SH et al and Yeh HC et al, also concluded that the declining lung function to be in inverse relation to diabetes severity and pulmonary function test parameters were significantly reduced except FEV1/FVC in patients of type 2 DM. [17,20] Meta-analysis by Borst BB et al, showed that DM is associated with an impaired pulmonary function in a restrictive pattern.13 Patients with type 2 DM were at increased risk of several pulmonary conditions like-asthma, Chronic Obstructive Pulmonary Disease (COPD), fibrosis and pneumonia. A study by Sinha et al, and Benbassat et al, failed to observe a significant difference in any of the PFT parameter except for DLCO and reported a lack of association. [16,21]

Normal lung mechanics and gas exchange are influenced by the integrity of the pulmonary connective tissue and microvasculature. Acceleration of aging process in connective tissue cross-links and presence of nonenzymatic glycosylation and modification of alveolar surfactant action causes a reduction in PFTs. There have been reports of histopathological changes in the diabetic patients. [21] Diabetic microangiopathy might be existing in the pulmonary vascular bed. Moreover, reduced pulmonary capillary blood volume was found, favoring the evidence of microangiopathy. This could lead to a redistribution of the pulmonary circulation resulting in well-ventilated areas to become under-perfused. [22] The thorax and lungs are rich in collagen and elastin. Stiffening of thorax and lung parenchyma can occur because of nonenzymatic glycosylation of these structural compounds. This may lead to the restrictive pattern. In this study, restrictive pattern in DM patients strongly suggests this mechanism of derangement in PFT. Duration of diabetes was significantly associated with the restrictive pattern in this study is further strengthens this hypothesis. With increasing duration of disease, the more exposure of the tissues and microvasculature to the hyperglycemic environment is expected and thus nonenzymatic glycation will also increase.

However, there are certain studies showing no correlations between HbA1c and PFTs. They argued that HbA1c levels are indicators of glycemic control for a short period of 1-2months, it was not adequate to conclude that the plasma glucose level was not related to decreased PFTs. While some studies have shown that the decline in PFTs was negatively correlated with HbA1c. [16,23,24]

In present study, FVC (L) P showed mild downstream correlation with age and duration of diabetes. No correlation with BMI and the HbA1c level was observed. Correlation of FVC (L) %P was found to be mild downstream with duration of disease only. FEV1 (L) P and FEV1 (L) %P also showed similarly mild downstream correlation with duration of disease only and both failed to show correlation with any other parameters. FEV1/FVC% P also showed mild downstream correlation with duration of disease. So, in a nutshell, most of the PFT parameters showed Mild downstream correlation with duration of disease. None of the parameters were found to show correlation with HbA1c. Marvisi M et al, found that both HbA1c and age of subjects showed no correlation with deranged PFT (DLCO). However, microangiopathy i.e. diabetic nephropathy and diabetic retinopathy both showed strong and moderate correlation respectively. This duration and control dependent complications can be considered surrogate markers for the duration of disease and long-term glycemic control and thus it can be extrapolated that the PFT is related to the duration of disease and long-term glycemic control.24 Similarly, Ljubić S et al revealed that the age, duration

of diabetes and complication parameters were found to be significant predictors of DLCO/VA. However, proteinuria was the only significant independent predictor of DLCO/VA. [25] There are certain studies showing no correlation between HbA1c and PFTs which support this finding. It might be due to that HbA1c levels are indicators of glycemic control for a short period of 1-2months, it was not adequate to conclude that the plasma glucose level was not related to decreased PFTs.

CONCLUSION:

Results of present study showed most of the patients belonged to 6th decade of life, male patients found with higher number as compared to female patients. In most of the diabetics, pulmonary function test was normal. Higher number of patients found with abnormal HbA1c levels.

REFERENCES:

1. American Diabetes Association. Standards of medical care in diabetes-2012. Diab Care. 2012;35(1):S11-63.
2. King H, Aubert RE, Herman WH. Global burden of diabetes: prevalence, numerical estimates, and projections. Diab Care. 1998;21(9):1414-31.
3. Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, Das HK, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR–INDIAB population-based cross-sectional study. Lancet Diab Endocrinol. 2017;5(8):585-96.
4. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The wisconsin epidemiologic study of diabetic retinopathy: II. prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102(4):520-6.
5. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. In: Fisman EZ, Tenenbaum A, eds. Cardiovascular Diabetology: Clinical, Metabolic and Inflammatory Facets. Karger: 2008;45:1-16.
6. Emerging risk factors collaboration. diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative metaanalysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22.
7. Borch-Johnsen K, Neil A, Balkau B, Larsen S, Nissinen A, Pekkanen J, et al. Glucose tolerance and cardiovascular mortality-comparison of fasting and 2hr diagnostic criteria, the DECODE study group: glucose tolerance and cardiovascular mortality comparison of fasting and 2hr diagnostic criteria. Arch Inter Med. 2001;161:397-405.
8. Boussageon R, Bejan-Angoulvant T, SaadatianElahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death and microvascular events in type 2 diabetes: metaanalysis of randomised controlled trials. BMJ. 2011;343:d4169.
9. Walter RE, Beiser A, Givelber RJ, O'connor GT, Gottlieb DJ. Association between glycemic state and lung function: the Framingham Heart Study. Am J Resp Critical Care Med. 2003;167(6):911-6.
10. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the cardiovascular health study. Diab. 2001;50(10):2384-9.
11. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. In: Fisman E.Z., Tenenbaum A, eds. Cardiovascular Diabetology: Clinical, Metabolic and Inflammatory Facets. Karger: 2008;45:1-16.
12. Davis TM, Knuiman M, Kendall P, Vu H, Davis WA. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle diabetes study. Diab Res Clin Prac. 2000;50:153-9.
13. Van den Borst B, Gosker HR, Zeegers MP, Schols AM. Pulmonary function in diabetes: a metaanalysis. Chest. 2010;138(2):393-406.
14. Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Cox CE, et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the atherosclerosis risk in communities (ARIC) study. Diab Care. 2008;31(4):741-6.
15. Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle diabetes study. Diab Care.
16. 2004;27(3):752-7.
17. Benbassat CA, Stern E, Blum I, Kramer M, Lebzelter J, Fink G. Pulmonary function in patients with diabetes mellitus. Am J Med Sci. 2001;322(3):127-32.
18. Shah SH, Sonawane P, Nahar P, Vaidya S, Salvi S. Pulmonary function tests in type 2 diabetes mellitus and their association with glycaemic control and duration of the disease. Lung India: Off Organ Ind Chest Soc. 2013;30(2):108.
19. Acharya PR, D'Souza M, Anand R, Kotian SM. Pulmonary function in type 2 diabetes mellitus:

correlation with body mass index and glycemic control. Inter J Sci Study. 2016;3(11):18-23.
20. Davis TM, Knuiman M, Kendall P, Vu H, Davis WA. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle diabetes study. Diab Res Clin Prac. 2000;50:153-9.
21. Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Brancati FL. Vital capacity as a predictor of incident type 2 diabetes: the atherosclerosis risk in communities' study. Diab Care. 2005;28(6):1472-9.
22. Sinha S, Guleria R, Misra A, Pandey RM. Pulmonary functions in patients with type 2 diabetes mellitus and correlation with anthropometry and microvascular complications. Ind J Med Res. 2004;119(2):66.
23. Mori H, Okubo M, Okamura M, Yamane K, Kado S, Egusa G, et al. Abnormalities of pulmonary function in patients with non-insulin-dependent diabetes mellitus. Inter Med. 1992;31(2):189-93.
24. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108(12):1527-32.
25. Marvisi M, Bartolini L, del Borrello P, Brianti M, Marani G, Guariglia A, et al. Pulmonary function in non-insulin-dependent diabetes mellitus. Respiration. 2001;68(3):268-72.
26. Ljubić S, Metelko Ž, Car N, Roglić G, Dražić Z. Reduction of diffusion capacity for carbon monoxide in diabetic patients. Chest. 1998;114(4):1033-5.